1-20 of 1446 Search Results for

androgen-deprivation-therapy

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5142.
Published: 15 June 2022
... outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving intensified androgen deprivation therapy (ADT) in a real-world population [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 661.
Published: 15 June 2022
... for these patients relies on androgen deprivation therapies (ADT) to block testosterone production combined with small molecules that inhibit androgen synthesis and/or the function of the androgen receptor (AR). Importantly, androgens are reported to be immunosuppressive; therefore, we postulated that androgen axis...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5316.
Published: 15 June 2022
...Shiv Verma; Eswar Shankar; Viabhav Singh; Sanjay Gupta Androgen deprivation therapy (ADT) is a commonly used clinical treatment for non-metastatic and metastatic hormone-sensitive prostate cancer. Long-term ADT treatment results in adverse side-effects in patients including depression, frailty...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5053.
Published: 15 June 2022
... nmCRPC. The multimodal approach demonstrates promise in treatment decision support for the early use of androgen receptor-directed therapy and patient selection for clinical trials with novel treatment combinations. Reference: 1. Mobadersany, Pooya, et al. "Predicting cancer outcomes from histology...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): CT171.
Published: 15 June 2022
...Lauri Rantaniemi; Aino Siltari; Eeva Harju; Teemu J. Murtola Introduction: Androgen-deprivation therapy (ADT) is standard in treatment of advanced prostate cancer (PCa). Common adverse effects include fatigue, weight gain, sarcopenia, and decreased libido leading to lowered quality of life (QoL...
Journal Articles
Cancer Res (2021) 81 (13_Supplement): 710.
Published: 01 July 2021
... for SARS-CoV-2 infection. Recent reports have shown that prostate cancer (PCa) patients undergoing androgen-deprivation therapies (ADT) were partially protected from COVID-19. The human myxovirus resistance gene 1 (MX1) is expressed in many tissues, including prostate, and we have previously demonstrated...
Journal Articles
Cancer Res (2021) 81 (13_Supplement): 2560.
Published: 01 July 2021
...Alexandra M. Vaiana; Roman Fernandez; Jonathan Gelfond; Teresa L. Johnson-Pais; Robin Leach; Chethan Ramamurthy; Ian Thompson; David A. Morilak Androgen deprivation therapy (ADT) is a frontline treatment for prostate cancer but induces profound cognitive impairment in more than half of patients...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 776.
Published: 15 August 2020
... in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 5610.
Published: 15 August 2020
..., effectively reduced growth in a subset of prostate tumors. In this setting, TAS-115 decreased tumor burden by reducing tumor neovascularization and promoting anti-tumor immune activity, however, this phenomenon was not observed when co-administered with androgen deprivation therapy (ADT) which is the primary...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 5750.
Published: 15 August 2020
...Alexandra M. Vaiana; Jonathan Gelfond; Teresa Johnson-Pais; Robin Leach; Michael Liss; Anna Sullivan; Ian Thompson; David A. Morilak First-line treatment for prostate cancer includes androgen deprivation therapy (ADT). However, this intervention can induce severe cognitive impairments in more than...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 618.
Published: 15 August 2020
...Maria J. Merino; Esra Dikoglu; Peter Pinto; Baris Turkbey; William Dahut; Guinevere Chun; Ravi A. Madan; Fatima Karzai Background: In this study we report the effects of neoadjuvant enzalutamide (enza) plus androgen deprivation therapy (ADT) in the prostatectomy specimens of patients receiving...
Journal Articles
Cancer Res (2022) 82 (13): 2417–2430.
Published: 05 July 2022
...Liang Qin; Yoon-Mi Chung; Michael Berk; Bryan Naelitz; Ziqi Zhu; Eric Klein; Abhishek A. Chakraborty; Nima Sharifi Androgen deprivation therapy suppresses tumor androgen receptor (AR) signaling by depleting circulating testosterone and is a mainstay treatment for advanced prostate cancer. Despite...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1301.
Published: 15 June 2022
... pleiotropic functions in prostate cancer; they are potent drivers of cancer cell growth and can suppress T cell function. In metastatic prostate cancer, intratumor androgen levels can remain high. Androgen deprivation therapy, the backbone of clinical care in prostate cancer, is classically administered...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5604.
Published: 15 June 2022
... of treatment. Additional analyses showed that androgen deprivation therapy induced an adenosine high signature, and increased Nt5e expression levels and CD73-positive infiltrating MDSCs/neutrophils. The efficacy of AZD4635 versus aCD73 plus AZD4635 was evaluated in an in vivo castration-sensitive model of Pten...
Journal Articles
Cancer Res CAN-22-1829.
Published: 24 October 2022
... AJ, Xing Y, Chen HW, et al. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. J Steroid Biochem Mol Biol 2019;193:105415 77. Kwilas AR, Ardiani A, Gameiro SR, Richards J, Hall AB, Hodge JW. Androgen deprivation therapy sensitizes triple negative breast...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5211.
Published: 15 June 2022
...Marco A. De Velasco; Yurie Kura; Naomi Ando; Noriko Sako; Kazuko Sakai; Kazutoshi Fujita; Eri Banno; Masahiro Nozawa; Kazuhiro Yoshimura; Kazuto Nishio; Hirotsugu Uemura Prostate cancers depend on androgens and the androgen receptor (AR) to drive androgen signaling pathways. Androgen-deprivation...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 122.
Published: 15 June 2022
...Liang Qin; Yoon-Mi Chung; Michael Berk; Bryan Naelitz; Eric Klein; Abhishek A Chakraborty; Nima Sharifi Androgen deprivation therapy depletes circulating testosterone and is the mainstay treatment for advanced prostate cancer by suppressing tumor androgen receptor signaling. Despite initial...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1438.
Published: 15 June 2022
... dose-response meta-analysis with additive allele coding. Results: Of the 3208 men in the prospective cohort study, 96% were diagnosed with clinically localized (T1/T2) prostate cancer. Most were treated with radical prostatectomy (47%) or radiation (36%); 33% ever received androgen deprivation therapy...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1483.
Published: 15 June 2022
...Joshua M. Corbin; Maria J. Ruiz-Echevarria The goal of this study is to identify RNA interference (RNAi) seed sequences that inhibit androgen signaling and induce toxicity in prostate cancer (PCa) cells. The high prevalence of acquired resistance to androgen deprivation therapy, as well as first...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2923.
Published: 15 June 2022
...Claire L. Soave; Charles Ducker; Nathan Nicely; Yanfang Huang; Luke Pardy; Peter Shaw; Manohar Ratnam Prostate cancer (PC) is generally dependent on the androgen signaling axis for growth. Advanced PC is managed by androgen deprivation therapy (ADT). However, the tumors frequently progress...